Chorea, remitting, with nystagmus and cataract

Summary

Chorea, remitting, with nystagmus and cataract (MONDO:0011061) is a disease. A subtype of choreatic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chorea, remitting, with nystagmus and cataract
Mondo ID	MONDO:0011061
MeSH	C535355
OMIM	601372
UMLS	C1832422
MedGen	330463
GARD	0009606
Is cancer (heuristic)	no

Also known as: chorea, remitting with nystagmus and cataracts · chorea, remitting, with nystagmus and cataract · familial remitting chorea, nystagmus and cataracts

Disease family

This is a subtype of choreatic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › choreatic disease › chorea, remitting, with nystagmus and cataract

Related subtypes (4): chorea gravidarum, choreoathetosis, familial inverted, chorea, benign familial, hereditary progressive chorea without dementia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.